OOIR: Observatory of International Research

Papers

(The TQCC of Nature Reviews Gastroenterology & Hepatology is 15. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)

Article	Citations
Zolbetuximab treatment in metastatic gastric cancer	706
Hybrid EASL Congress 2023	668
Celebrating 20 years of Nature Reviews Gastroenterology & Hepatology	646
Mirikizumab for inducing and maintaining clinical remission in ulcerative colitis	574
Mapping neuroimmune interactions in the gut	564
New potent HBV replication inhibitors for the management of chronic hepatitis B are needed	509
2023 FDA approvals in gastroenterology and hepatology	500
Author Correction: Towards unifying fatty liver nomenclature: a voice from the Middle East and North Africa	439
The role of the enteric nervous system in the pathogenesis of Clostridioides difficile infection	353
Western lifestyle, metaflammation and the cell of origin of colon cancer	339
Advancing nutrition science for global health	300
The future of treating pancreatic exocrine insufficiency	298
Digestive Disease Week 2022	286
Unlocking CD8+ T cell potential in chronic hepatitis B virus infection	272
Nomenclature of HBV core protein-targeting antivirals	271
Helicobacter pylori, microbiota and gastric cancer — principles of microorganism-driven carcinogenesis	253
Artificial intelligence and automation in endoscopy and surgery	243
Black–White disparities across the colorectal cancer care continuum in the USA	242
Large language models for clinical decision support in gastroenterology and hepatology	224
The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of gut health	222
New understanding of hepatobiliary MRI	218
Metastatic pancreatic cancer and the liver	210
Lessons from incretin-based therapy in MASH and obesity	198
Food as medicine in gastrointestinal cancer therapy	191
Novel insights into chronic HBV infection	191

The gut–brain axis and pain signalling mechanisms in the gastrointestinal tract	187
CAR T cell therapies in gastrointestinal cancers: current clinical trials and strategies to overcome challenges	181
A crucial Fusobacterium nucleatum clade in colorectal cancer	174
The changing metabolic landscape of bile acids – keys to metabolism and immune regulation	172
Balancing cholesterol metabolism in the liver and gut: perspectives in health and disease	171
The critical role of gut–brain signalling in eating behaviour and obesity	170
Inflammatory bowel disease in pregnancy and breastfeeding	164
A greener gastroenterology: challenges and opportunities for an eco-sustainable approach to digestive diseases	160
Hepatocyte-derived biomarkers in alcohol-related cirrhosis	158
Integrated systems approach to identify environmental factors in intestinal inflammation	154
Characterizing the genomic landscape of colorectal cancer	148
Implications of the evolving knowledge of the genetic architecture of MASLD	146
Liver, ageing and disease	142
Probiotics for preterms: sharing complex decision-making	138
Estimating dietary intake from human stool DNA	136
HDCA ameliorates NAFLD in mice	129
Preventing the progression of cirrhosis to decompensation and death	127
Medical therapy of paediatric inflammatory bowel disease	123
SSRIs and depression: role of gut–brain communication	117
Irritable bowel syndrome and mental health comorbidity — approach to multidisciplinary management	110
The path to successful hepatitis C elimination in Spain	109
Author Correction: Μetabolic dysfunction-associated steatotic liver disease: a condition of heterogeneous metabolic risk factors, mechanisms and comorbidities requiring holistic treatment	103
Clinical trial design, biomarkers and end points in metabolic and alcohol-related liver disease	101
Metabolic diseases in the East Asian populations	99
Proteases in intestinal health and disease	95
Human intestinal B cells in inflammatory diseases	93
A roadmap for serum biomarkers for hepatitis B virus: current status and future outlook	92
Phase III results for first-line treatment for metastatic colorectal cancer	91
NAFLD prevalence in older patients with T2DM	91
Microbiota and colorectal cancer — controlling for confounders challenges associations	83
ECCO’24	83
Reply to ‘Incorporating genetic variations in alcohol-associated liver disease trials for East Asian populations’	83
Enteric nervous system transfers stress to the gut	82
Risk minimization of JAK inhibitors in ulcerative colitis following regulatory guidance	75
The future of pathology in gastroenterology and hepatology	72
HIV-associated gut microbiome influences gut mucosal immunity	71
Transforming the landscape of liver cancer detection and care	70
Human deskilling in medical artificial intelligence: prohibited or permissible under the EU Artificial Intelligence Act?	67
Author Correction: Hepatic immune regulation and sex disparities	66
GLP1R agonists in NAFLD: a promising therapy on the horizon	66
Artificial intelligence in liver cancer — new tools for research and patient management	64
Hepatic glucose metabolism in the steatotic liver	64
SMART cancer risk prediction	62
AI predicts pancreatic cancer risk	62
Hepatic inflammatory responses in liver fibrosis	62
Liver dialysis in ACLF	62
Gut bacteria go on record	61
Nifty new tools for microbiome treatment design	60
International collaborative research to improve gallbladder cancer prevention	60
A new era in obesity management	58

A neurobiotic sense curbs feeding: a new frontier in gut–brain communication	57
Nutrient sensing and small intestinal enteric neurons	55
Elucidating the transmission landscape of the human microbiome	55
Hepatitis E virus: from innate sensing to adaptive immune responses	54
A global consensus on the definitions, diagnosis and management of fibrostenosing small bowel Crohn’s disease in clinical practice	53
Future direction of total neoadjuvant therapy for locally advanced rectal cancer	53
MASLD as a non-communicable disease	53
Pushing the frontier of gut microbiome health cross-kingdom and cross-organ	52
Tirzepatide to treat obesity: phase III results	50
Microplastics, nanoplastics and liver disease: an emerging health concern?	49
Bridging the gap: increasing MENA representation in MASLD clinical trials	48
A novel pathomics signature for gastric cancer	47
The steatotic liver disease burden paradox: unravelling the key role of alcohol	47
Commensal fungi in intestinal health and disease	47
Preoperative chemotherapy, radiotherapy and surgical decision-making in patients with borderline resectable and locally advanced pancreatic cancer	46
Therapeutic landscape and future direction of metastatic colorectal cancer	46
Cathepsin S in liver fibrogenesis	45
Classifying compounds as prebiotics — scientific perspectives and recommendations	44
Cellular and molecular basis of proximal small intestine disorders	44
Changing epidemiology of colorectal cancer — birth cohort effects and emerging risk factors	44
Telemedicine for hepatitis C virus treatment in opioid treatment programmes	44
Antibiotic-perturbed microbiota and the role of probiotics	44
Long-term normothermic liver perfusion	42
Author Correction: Improving IBD outcomes in the era of many treatment options	41
Author Correction: Current and future colorectal cancer screening strategies	41
Diet-driven microbiome restoration associated with cardiometabolic benefits	40
Reply to ‘The ethics of unlicensed therapy use in primary biliary cholangitis: a counter view’	40
Alcohol-free and low-strength drinks: friend or foe?	38
Justice, equity, diversity and inclusion in gastroenterology and hepatology	37
Changes in cholera burden across Africa	37
A Roadmap for the Human Gut Cell Atlas	36
Pleasurable and problematic receptive anal intercourse and diseases of the colon, rectum and anus	36
Equitable partnerships and the path to inclusive, innovative and impactful human microbiome research	34
Gut virome dynamics: from commensal to critical player in health and disease	33
Defining the mucosal ecosystem: epithelial–mesenchymal interdependence in gastrointestinal health and disease	31
Antifibrotic therapy in nonalcoholic steatohepatitis: time for a human-centric approach	31
Public health policies to prevent alcohol-related liver disease	31
New target and timing in PDAC immunotherapy?	30
Global epidemiology of cirrhosis — aetiology, trends and predictions	30
Resmetirom safe for nonalcoholic fatty liver disease	29
Elafibranor in primary biliary cholangitis	28
ECCO’25	28
Digestive Disease Week 2023	27
A resource for the food microbiome and its links with the human microbiome	26
Digestive Disease Week 2025	25
Mechanisms of chronic abdominal pain in inflammatory bowel disease and implications for treatment	25
Intermittent fasting for NASH and HCC in mice	25
Tissue-resident memory CD8+ T cells: master deciphers of the hepatic environment	24
Positive longer-term results for efruxifermin in MASH	24
Microplastics and nanoplastics in the human gut: from signals to standards	23
Liver diseases and hepatocellular carcinoma in the Asia-Pacific region: burden, trends, challenges and future directions	22
Deciphering potential implications of dietary microplastics for human health	22
Envisioning how to advance the MASH field	22
Cholangiocarcinoma 2026: status quo, unmet needs and priorities	22
Autocrine signalling discovery reveals potential therapeutic targets in NASH fibrosis	21
Follow-up of SER-109 for recurrent C. difficile	21
Food inequity and insecurity and MASLD: burden, challenges, and interventions	21
HCV direct-acting antiviral therapy adherence in people who inject drugs	21
Human liver tissue in a mouse host	20
IL-17A-producing CD8+ T cells in pancreatic cancer	19
Amitriptyline as second-line treatment for IBS in primary care settings	19
Optimizing sacral nerve stimulation to relieve chronic constipation	19
Predicting mortality in cirrhosis	19
RNA vaccine induces long-lived anti-tumour T cells in pancreatic cancer	19
Liquid biopsy combined with machine learning predicts early detection in liver disease	17
Lactylation and HCC progression	17
The intersection between alcohol-related liver disease and nonalcoholic fatty liver disease	16
Nanoparticles in NAFLD therapeutics	16
Gastrointestinal health and the environment: a bidirectional relationship	16
Hepatocellular carcinoma surveillance — utilization, barriers and the impact of changing aetiology	16
Circadian regulation of liver function: from molecular mechanisms to disease pathophysiology	15